The latest from NuvOx

TUCSON, AZ, July 15, 2026 — NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track designation for NanO₂™ by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients presenting with acute ischemic stroke (“AIS”). Acute ischemic stroke remains a leading cause of death and long-term disability worldwide. Despite advances in mechanical t

Tucson, Arizona — April 30, 2026 — NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positive preliminary results from the second cohort of its ongoing EXTEND Phase Ib clinical trial of NanO₂™ (dodecafluoropentane emulsion) in patients with mild respiratory distress. The results demonstrated stronger oxygenation signals with dose escalation while maintaining an excelle

Tucson, AZ – April 22, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”), a clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics, today announced that it has entered into a research collaboration agreement with Department of Veteran Affairs (“VA”). The research project is to investigate whether NuvOx’s oxygen therapeutic product candidate, NanO₂™ (dodecafluoropentane emulsion), can improve oxygen delivery, as well as its

Tucson, AZ – March 10, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”) announced that the first patient has been treated under a U.S. Food and Drug Administration (FDA)-authorized single-patient Expanded Access protocol for newly diagnosed glioblastoma at the Center for Neurosciences. The treatment was administered by Dr. Michael Badruddoja and Dr. Matthew McFarlane, marking a significant milestone in NuvOx’s mission to address unmet needs in patients with a

Tucson, AZ –March 4, 2026, NuvOx Therapeutics, Inc. (“NuvOx”) today announced that the U.S. Food and Drug Administration (FDA) has authorized NuvOx to proceed with a new Phase II clinical trial evaluating NuvOx’s product candidate NanO 2 (the active pharmaceutical ingredient of which is dodecafluoropentane) for the treatment of recurrent high-grade gliomas. The study, titled REBORN (Radiation Enhancement with Bevacizumab, Lomustine, Oxygen Replenishment, and NanO 2 [DDFPe]